New therapeutic approach to Toxic Epidermal Necrolysis (TEN) using anti-CD38+ antibodies in the active phase of the disease – Phase I/II study to assess the tolerance and efficacy of DARATUMUMAB - NET-CD38 Study

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512164-63-00

Acronym

69HCL23_1000

Enrollment

Registered

2025-04-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Toxic Epidermal Necrolysis

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026